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Abstract: Exotic snakebites (i.e. from non-native species) are a rare occurrence, but they present a
unique challenge to clinicians treating these patients. Poison control centers are often contacted to
assist in the management and care of these medical emergencies. In this study, we analyzed case
records of the two Pennsylvania poison control centers from 2004 to 2018 to describe clinical features
reported as a result of exotic snakebite envenomation. For the 15-year period reviewed, 18 exotic
snakebites were reported with effects ranging from mild local tissue injury to patients who were
treated with mechanical ventilation due to respiratory failure. The mean age of the patients was
35 years and males accounted for 83% of the cases. Antivenom, the only specific treatment, was
administered in seven of 18 patients within an average of four h of envenomation. The procurement
of antivenom against these exotic species may require substantial logistical efforts due to limited
stocking of this rarely used treatment. Newer, targeted, small molecule treatments that are being
currently investigated may aid in the treatment of snakebites in general. However, people should
be cautious when handling these exotic species, and clinicians should be aware of these bites and
relevant clinical effects in order to manage these when reported.
Keywords: snakebite; envenomation; exotic; non-native; United States; poison center; antivenom
Key Contribution: This paper describes the demographics, clinical effects and treatment of exotic
snakebites reported to Pennsylvania Poison Control centers during the 15-year period (2004–2018).
1. Introduction
While fear of snakebites is relatively common, fatalities from snakebite envenomation (SBE)
are a rare occurrence in industrialized countries due to prompt access to appropriate medical care.
Globally, estimates of annual fatalities range from 80,000 to over 120,000 are likely to be underestimated
due to a lack of reporting in the rural areas of less developed countries where snakebites are most
prevalent [1,2]. Most of the SBE occur in rural areas of South and Southeast Asia, Sub-Saharan Africa,
Oceania, and South America [3–5]. The access to medical facilities is limited in these regions. However,
in the United States of America (USA), venomous snakebites occur primarily in the Southern and
Western states with annual estimates ranging from a few thousand to 6000 or more resulting in less
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than 20 fatalities [6,7]. The vast majority of these bites are caused by viperid species native to North
America and consist of rattlesnakes (Crotalus spp.), copperheads, cottonmouths (Agkistrodon spp.),
and a small number of elapid coral snakes (Micrurus spp.) [8]. In the USA., exotic, non-native species
are estimated to cause over 30 SBE per year [9,10]. The trade in venomous snakes increases risks to the
public via exposure to these potentially dangerous creatures as well as creating pressure on wild snake
populations [11]. The clinical effects of envenomation from these exotic species have been described
more generally using broad descriptive terms [9]. Most often, the American Association of Poison
Control Center designations for clinical outcomes such as mild, moderate or severe are utilized to
describe data collected from these victims.
In an effort to provide a comprehensive picture of exotic snakebites reported to Pennsylvania’s
two poison control centers, we critically analyzed exotic SBE cases from 2004 to 2018. The Pennsylvania
poison control centers are based in Philadelphia and Pittsburgh and serve a state population of
12.7 million people. The Philadelphia Poison Control Center also services the State of Delaware with a
population of approximately 1 million. However, no exotic SBE was reported from this state. Here,
we present the demographics and clinical effects of exotic SBE cases as well as treatments used for the
management of these victims.
2. Results
2.1. Original Data Extraction
A total of 1452 human exposure calls coded as ‘snakebite’ for the study period (2004–2018)
were reported to the Pennsylvania Poison Control Centers, and 847 of these cases were subsequently
identified as venomous snakebites. Out of these, 18 cases were determined to be non-native snakebites,
and these were included in the analysis for this study (Table 1).
Table 1. Exotic snakebites by species, demographics, location, severity, and antivenom use.
Snake Species Age (Years) Gender Location of Bite Clinical Effects Antivenom (Yes/No)
Aspidelaps lubricus 44 M Hand Severe No
Atheris chlorechis 17 M Finger Unknown No
Atheris squamigera 30 M Finger Moderate No
Bitis arietans 50 F Face Severe Yes *
Bothrops schlegelii 42 M Finger Minor Yes
Crotalus durissus terrificus 36 M Finger Moderate Yes
Naja kaouthia 23 F Buttocks Severe Yes
Naja kaouthia 24 M Forearm Unknown No
Naja kaouthia 31 M Finger None No
Naja kaouthia 33 M Unknown Severe Yes *
Naja kaouthia ** Unknown M Unknown Unknown No
Naja melanoleuca 63 F Unknown Minor No
Naja pallida 16 M Hand Moderate Yes *
Naja siamensis 38 M Finger Moderate Yes *
Naja sumatrana 55 M Ocular Minor No
Trimeresurus albolabris 24 M Finger Minor No
Trimeresurus albolabris 28 M Hand Moderate No
Trimeresurus
purpureomaculatus 23 M Finger Moderate No
** Suspected dry bite, * Antivenoms procured from Philadelphia zoo in these cases.
2.2. Patient Demographics
Of these 18 cases, a majority of the cases (15 of 18, 83%), were males. The mean age of the patients
was 35 years (range from 16 to 63). Of note, three of the patients were also suspected of alcohol
intoxication, although blood ethanol levels were not reported. One victim was reported to have been
envenomed at a place of business, while the remaining were believed to have occurred within a private
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residence where the victim was either the owner of the exotic snake or an acquaintance of the owner.
Of the 18 cases reported, one was suspected a dry bite as no clinical effects were observed, and one case
was significant for an ocular exposure from an Equatorial spitting cobra (Naja sumatrana). In the case
of a suspected dry bite from a specimen of Naja kaouthia, the patient was evaluated in the emergency
department and left prior to the recommended observation period without returning. It is important to
note that the absence of any symptoms at arrival to a health care facility does not necessarily mean that
the patient has experienced a dry bite as symptoms may be delayed [12]. The fingers and hands were
the most common sites of envenomation. However, one patient was bitten on the face and another on
the buttocks.
2.3. Clinical Envenomation Effects
2.3.1. Local Effects
From the exotic SBE cases reported, four described local tissue effects that ranged from mild
redness at the bite site to diffuse edema and ecchymosis (Figure 1). The most significant local effects
occurred as a result of a Puff adder (Bitis arietans) envenomation which occurred in the submandibular
area. Diffuse ecchymosis and edema were reported extending from the bite site down to the neck and
chest in this victim. The neck circumference measurement increased from 45 cm to 54 cm. This patient
was endotracheally intubated due to the profound upper airway edema for over three weeks due to
a suspected ventilator-associated pneumonia, which complicated their recovery. Blisters were also
observed in two cases of Trimeresurus spp. envenomations and a bulla was seen in single patient with
an Atheris chlorechis bite. The bulla was drained and one of the blisters underwent minor debridement,
but no additional treatments were considered necessary for these local effects.
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Figure 1. Different types of clinical effects observed in 18 cases of exotic snakebite envenomation (SBE)
analyzed in this study. Some patients displayed multiple clinical effects.
2.3.2. Neurological Effects
Neurological effects were observed in four of 18 patients (22%) and included mild paresthesias
as well as life-threatening bulbar and respiratory paralysis (Figure 1). Elapid envenomation resulted
in the most significant neurological sequelae. An adult was bitten by both a juvenile and an adult
Cape Coral cobra (Aspidelaps lubricus) while placing his hand inside the cage. This patient developed
ptosis, dysphagia and upper extremity, facial, and respiratory paralysis, which resulted in endotracheal
intubation and medical helicopter transport to the hospital. The Monocled cobra (Naja kaouthia) was
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responsible for four SBE in our study (as stated above one dry bite was also reported for this snake).
Two of these patients underwent intubation due to bulbar involvement and respiratory paralysis. One
patient, bitten on the buttocks remained asymptomatic for eight h then developed diplopia, dysphagia,
and respiratory failure, and was therefore treated with mechanical ventilation. A single case of a
viperid snake causing neurotoxic effects was also reported; the South American rattlesnake, Crotalus
durissus, was involved in one bite to the finger of a 36-year-old patient, resulting in perioral paresthesia
and diplopia.
2.3.3. Hematological Effects
Changes in hematologic laboratory parameters were noted in five of 18 cases (28%) (Figure 1),
however clinically significant bleeding was not reported in any of them. Thrombocytopenia was
observed in two cases including one viperid, a Puff adder, Bitis arietans (platelets 84× 109/L; normal range
(150–400)× 109/L) and one elapid, a red spitting cobra, Naja pallida (platelets 102× 109/L). The Naja pallida
envenomation also resulted in an elevated d-dimer of 3.63 µg/mL (normal <0.4 µg/mL) and a prolonged
prothrombin time (PT) of 18.3 s (normal range 11–12.5 s). The single Puff adder envenomation resulted
in an initial fibrinogen value of 249 mg/dL (normal range 200–400 mg/dL) that declined to a nadir of
104 mg/dL. One white-lipped pit viper bite, Trimeresurus albolabris, resulted in a modest fibrinogen
decline from 224 to 185 mg/dL. Accurate timing of laboratory values was not readily available from
the case information. Antivenom was administered in all cases reporting changes in hematologic
laboratory values. Of the species causing hematological effects, all with the exception of Naja pallida
are recognized to have the potential for clinically significant bleeding.
2.3.4. Other Reported Clinical Effects
As mentioned above, one patient had an ocular exposure to a red spitting cobra and developed
irritation and conjunctivitis that resolved with saline irrigation in the health care facility (Figure 1).
No additional sequalae were observed in this patient. Pain at the site of envenomation was the most
common complaint reported in all cases. An elevated creatine kinase (CK) level was noted in three
of the cases. An envenomation from a Thai spitting cobra (Naja siamensis) caused a CK elevation of
over 16,000 U/L (normal range 39–308 U/L), however, subsequent rhabdomyolysis was not observed.
More modest CK elevations were noted in cases from Crotalus durissus (695 U/L) and Naja pallida
(497 U/L).
2.4. Treatments Provided for Exotic SBE
Antivenom was administered to seven of 18 patients (39%) within an average of four h from the
time of envenomation (range three to nine h) (Figure 2). Time to antivenom administration data was
available for five of the seven cases. The antivenom from South African Institute of Medical Research
(SAIMR) was utilized in three cases, one viperid, Bitis arietans, and two elapids, Naja siamensis and Naja
kaouthia. The polyvalent immune fab (CroFab®-BTG International) was administered in the single case
of Crotalus durissus envenomation. The type of antivenom was not documented in three of the reported
cases. The single patient treated with CroFab®(BTG) did not report any adverse effects, however two
of the cases requiring SAIMR antivenom reported some minor shaking during administration. No
serious adverse effects were noted. Early administration of antivenom is important and may result in
faster limb recovery [13].
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Figure 2. Nature of treatment provided for the exotic SBE cases reported in this study. Some patients
received multiple interventions.
The cholinesterase inhibitors, pyridostigmine or neostigmine were given prior to antivenom
in two of the reported Naja kaouthia envenomations (Figure 2), but the effectiveness was not noted.
Mechanical ventilatio was provided in fou patients, three elapid bites, Naja spp pallida, siamensis,
and kaouthia due to neu ological effects and a viperid bite by Crotalus durissus due to edema as d scrib
above. Wound care was provided to patients as necessary, including incision and drainage of a bu la
and debrid ment of several wounds. Pre-hospital measures were self-performed in thre patients.
Of these, one patient reportedly incised his site of envenomation and two patients used tourniquets
applied to the affect d ar as. Incisi ns and ourniquets are not recommended and can actually worsen
outcomes by causi g seriou damag including cellulitis or limb gangrene [14].
2.5. Time Spent in Health Care Facility
Following envenomation, patients arrived in h spitals ither by private tra sport or via e ergency
medical services. Specific tra sport information was not available from th data reviewed. Two ca es
were admitted to a general medical-surgical floor for an average of 22 h. A total of seven patients were
treated i the Inten ive Care Unit (ICU). Time pent in the ICU averaged 124 h d ranged from 16
to 576 h. Of t se patients, six received ICU care for less than five days, whil a single patient with
compli tions from a Puff adder bite remained for over three w eks. The remaining nine patients spent
le s than 24 h in the Emergency Department (ED).
3. Discussion
Exotic SBE has been reported in s veral regions of western countries. Envenomation may occur
during handling or maintaining pet enclosures or other equip ent. Due to reports of these bites in the
USA, this study has identified and described detailed demographics, clinical effect and treatments
as a r sult o exotic (non-native) snakebites reported to Pennsylvania Poison Control C nters for the
15-year period of 2004–2018. Of 1452 reported snakebite cases, a otal of 18 (1.24%) were caused by
sn kes that are not native to North Am rica. Clinical effects ranged from n asymptomatic patient
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from a presumed ‘dry bite’ to patients that received mechanical ventilation, one for several weeks due
to complications.
Our work reported similar findings to a 2014 study that examined 258 exotic snakebites within
the USA from 2005 to 2011 [9]. The mean age of patients in the present study was 35 years,
including 83% males compared with a mean age of 33 years and 79% males in the national study.
Antivenom was administered similarly with 39% receiving doses in this regional study versus 35%
nationally. Adverse effects to antivenom were reported in 11% of our cases and these were generally
mild in nature. This was higher than the reported 2.3% for the national study but far below the 20–80%
that has been reported in some Asian studies [15]. Interestingly, Naja kaouthia accounted for the greatest
number of SBE in both studies, perhaps reflecting greater availability, affordability, or reptile owner
interest. This species was also noted to have been involved in a large number of SBE in a 1996 study
that reported on non-native snakebites from 1977 to 1995 [16]. Bites from Trimeresurus spp, Atheris spp,
and additional Naja species were the next most commonly reported exposures.
The USA is not alone with regard to exotic SBE. A study that analyzed case inquiries to the
United Kingdom National Poisons Information Service from 2004 to 2010 reported that 3% of all
venomous snakebites in the UK were attributed to exotic species [17]. Similar to our data, the UK
study reported that 69% of the cases were males with a mean age of 32 years of age. A poison center
report from Hong Kong also describes several exotic snakebites [18]. A 34-year-old snake breeder in
Switzerland was unknowingly envenomed by a black mamba (Dendroaspis polyepis) while feeding a
specimen and a medical helicopter was used to transport antivenom to the treating hospital [19].
Elapid envenomation characteristically results in neurologic effects, whereas viper bites often
present with hematological complications and local tissue injury. However, several of our cases
demonstrate that clinical effects may overlap between these two families due to species-specific
toxins [20]. For example, our case of the elapid, Naja pallida envenomation did report elevated
prothrombin time and d-dimer level as well as thrombocytopenia. These findings reveal an
anticoagulant effect that was recently demonstrated in a study of various cobra venoms [21]. Crotoxin is
a component of the venom of the viperid South American rattlesnake, Crotalus durissus and is
a potent phospholipase (PLA2) neurotoxin. The predominant effects of this toxin appear to be
inhibition of neurotransmission at the pre-synaptic level. However, some post-synaptic effects are also
possible [22,23]. Consistent with this toxin, our single case of Crotalus durissus envenomation reported
both diplopia and paresthesias. While the majority of our cases suffered bites to the arms and hands,
one patient was envenomed on the buttocks. This patient presented with delayed neurological effects
eight h after the bite. The delay in onset of symptoms raises the question of possible slowed venom
absorption due to site of envenomation, although we cannot rule out the possibilities of other factors
including a minimal/diluted venom being injected.
Exotic snakebite is a rare occurrence in the USA and affords unique challenges to healthcare
providers, many of whom have never cared for a snakebite victim previously. Interestingly, in areas
where “exotic” species are endemic, such as Africa and parts of Asia, healthcare providers face obstacles
in treatment and diagnosis as well, occasionally for different reasons. Frequently in the USA, exotic SBE
occurs as a result of a reptile owner or acquaintance who has been bitten while handling the snake.
In these cases, the victims typically know the species of snake since it has been purchased and cared
for by the owner. In our case of a Naja melanoleuca bite, the owner had purchased antivenom prior
to the envenomation and was able to bring the product with them to the hospital for treatment.
Providers in many locations frequently have to deal with wild bites in which the offending snake is
unable to be identified, thus complicating treatment decisions. These bites primarily occur in poor
rural communities affecting agricultural workers, herders, fishermen, hunters, and inhabitants of
improper housing. Antivenom procurement is a difficulty, which may be experienced by physicians
and other providers both in the USA and abroad. In the USA, antivenom for exotic snakes is typically
not stocked within hospitals but most often located at zoos, which are generous enough to make
the product available for emergencies. An index of available antivenoms is available through the
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Association of Zoos and Aquariums and the School of Pharmacy at the University of Arizona. As these
products are utilized very infrequently, many vials in the supply are outdated. Nevertheless, outdated
products are used in situations where no alternatives are available. The antivenom may be located
many miles from the treating facility, necessitating transport via helicopter as was necessary in two of
our cases. Overseas providers face logistical challenges with antivenom as well. However, in many of
these cases, health care facilities simply lack supply of the antivenom due to shortages or discontinued
products [24]. The lack of appropriate antivenom for these exotic species is one of the major challenges
in managing these bites.
Although antivenom is currently the only specific treatment utilized for SBE, there remain many
difficulties surrounding its use. Procurement of antivenom can be challenging not only in rural
areas of impoverished countries but also in cities of industrialized nations including the USA as well.
Fortunately, newer non-antivenom therapeutics are being investigated, which may help to delay,
prevent, or ameliorate the effects of envenomation, thus providing additional time for antivenom to
be provided. Varespladib is a sPLA2 inhibitor that is being investigated for potential use as first-line
treatment for SBE [21]. PLA2s are components of many venoms and produce significant pathological
effects. Similarly, batimastat and marimastat are broad-spectrum matrix metalloprotease inhibitors
which have been demonstrated to reduce the destructive effects of snake venom metalloproteases
(SVMPs) [25,26]. A preliminary report of a combination of varespladib and marimastat, showed promise
in an in vivo mouse model of SBE. This same study also reported the inhibition of a snake venom
serine protease (SVSPs) by an inhibitor compound, nafamostat [27]. Additionally, other studies have
investigated hyaluronidase inhibitors as potential agents for treating SBE [28–30].
The collection of reptiles and their maintenance is a popular hobby and many amateur collectors
may easily obtain venomous species through the mail or by visiting reptile trade shows. Federal and
state regulations can be ambiguous and the responsibility often falls to local government agencies to
enact measures to control these potentially dangerous animals [31]. Even responsible, professional
collectors are occasionally bitten, necessitating life-saving intervention. SBE is not only causing
deaths, but also resulting in extensive skeletal muscle damage which frequently leads to permanent
disabilities [32,33]. Moreover, SBE (specifically from vipers) can alter cardiovascular system, such as
the function and number of platelets (as demonstrated in this study), which subsequently leads to
thromboinflammatory complications [34–36]. Hence, it is critical to prevent SBE specifically from
non-native species for which antivenom may not be readily available.
Our study is limited by the data within the National Poison Data System (NPDS) and the
self-reporting by hospitals to poison control centers. As information is voluntarily reported,
some clinical details may be incomplete or specific data may be subjectively reported by individuals
caring for the patients. We were also limited by the lack of long-term follow-up which might enable
us to track any prolonged injuries, side effects or permanent disabilities. In some cases, the details
may be underreported as owners are fearful of legal repercussions and fail to seek medical assistance.
Additional areas of future research might include a detailed cost analysis of treatments and long-term
follow-up of patients to determine the extent of recovery. Despite these limitations, this study has
highlighted the nature of exotic SBE among the developed communities, and the challenges they pose
to clinicians during the clinical management of these cases. It is important that both the snake owners
and relevant health authorities take into consideration potential SBE and the challenges in treating
them while planning/permitting the purchase of such species.
4. Materials and Methods
For the initial data set, the NPDS database of the Philadelphia and Pittsburgh Pennsylvania Poison
Control Centers, was searched from 2004 to 2018 using generic codes 0137000, and 0137102-013710.
These internal codes are used to designate specific products, natural substances, animals, or other
features relating to poisoning or envenomation. As described above, Delaware is included in the
Philadelphia Poison Control Center service area. However, no exotic snakebites were reported from
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within this state. All 18 SBE described in this study were reported to have occurred within the State of
Pennsylvania in the USA. This study was exempted from the Institutional Research Board for ethical
considerations and only anonymized data were used. The de-identified records were abstracted.
The demographic and clinical data were extracted from individual patient charts utilizing pre-defined
criteria and placed into a spreadsheet. All the anonymized data were thoroughly checked for accuracy
prior to analysis in this study.
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